Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

about

Aprepitant and fosaprepitant drug interactions: a systematic review.Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.Safety of Polysorbate 80 in the Oncology Setting.

P2860

Q39282847-2DBBED12-250F-44F2-8DB6-0AFE00006343 Q53837638-11DA3D04-0078-4401-AE7F-5A5DE4026FCA Q55405018-0F59D764-4387-4F72-B4D5-65D9DA5528CD

P2860

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

Item

http://www.wikidata.org/entity/Q39653943

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Infusion site adverse events i ...... t: A retrospective comparison.

@en

Infusion site adverse events i ...... t: A retrospective comparison.

@nl

type

Item

label

Infusion site adverse events i ...... t: A retrospective comparison.

@en

Infusion site adverse events i ...... t: A retrospective comparison.

@nl

prefLabel

Infusion site adverse events i ...... t: A retrospective comparison.

@en

Infusion site adverse events i ...... t: A retrospective comparison.

@nl

P1476

Infusion site adverse events i ...... t: A retrospective comparison.

@en

P2093

Chisato Kyomori

http://www.w3.org/2001/XMLSchema#string

Koichiro Tsugawa

http://www.w3.org/2001/XMLSchema#string

Mami Hirakawa

http://www.w3.org/2001/XMLSchema#string

Naoki Izawa

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

Takako Eguchi Nakajima

http://www.w3.org/2001/XMLSchema#string

Takashi Ogura

http://www.w3.org/2001/XMLSchema#string

Takashi Tsuda

http://www.w3.org/2001/XMLSchema#string

Takuro Mizukami

http://www.w3.org/2001/XMLSchema#string

Tomoko Taniyama

http://www.w3.org/2001/XMLSchema#string

P2860

Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

P304

603-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2016.769

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

293190071

http://www.w3.org/2001/XMLSchema#string

P698

27073673

http://www.w3.org/2001/XMLSchema#string

P932

4812534

http://www.w3.org/2001/XMLSchema#string

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

about

P2860

P2860

Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932